Roche strikes deal with Memory Pharmaceuticals. (Supplier News).Roche has acquired an exclusive worldwide license from Memory Pharmaceuticals to develop compounds for the treatment of Alzheimer's disease Alzheimer's disease (ăls`hī'mərz, ôls–), degenerative disease of nerve cells in the cerebral cortex that leads to atrophy of the brain and senile dementia. . Roche and Memory also will develop compounds within the same drug class for other indicators, such as depression. The first drug candidate for alzheimer's disease is scheduled to enter human clinical trial in the near future. Roche will make upfront, research and development, and milestone payments to Memory. If all potential milestones are achieved, the deal will amount to approximately $150 million (U.S.) Roche will also pay royalties to Memory. Roche, headquartered in Basel, Switzerland, is a research-oriented health group in the fields of pharm ceuticals, diagnostics, and vitamins. Memory Pharmaceuticals, based in Montvale, N.J., is a neuropharmaceutical company developing drugs for the treatment of cognitive disorders in neurological neurological, neurologic pertaining to or emanating from the nervous system or from neurology. neurological assessment evaluation of the health status of a patient with a nervous system disorder or dysfunction. and psychiatric psy·chi·at·ric adj. Of or relating to psychiatry. psychiatric adjective Pertaining to psychiatry, mental disorders disease and aging. CLTC CLTC Certified in Long-Term Care CLTC Community Long Term Care CLTC Chapter Leadership Training Conference |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion